Reproducibility issues in science, is P value really the only answer? by Gaudart, Jean et al.
Reproducibility issues in science, is P value really the
only answer?
Jean Gaudart, Laetitia Huiart, P. J. Milligan, Rodolphe Thiebaut, Roch
Giorgi
To cite this version:
Jean Gaudart, Laetitia Huiart, P. J. Milligan, Rodolphe Thiebaut, Roch Giorgi. Reproducibil-
ity issues in science, is P value really the only answer?. Proceedings of the National Academy
of Sciences of the United States of America , National Academy of Sciences, 2014, 111 (19),
pp.e1934. <http://www.pnas.org/content/111/19/E1934.full>. <10.1073/pnas.1323051111>.
<hal-01307492>
HAL Id: hal-01307492
https://hal-amu.archives-ouvertes.fr/hal-01307492
Submitted on 26 Apr 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0
International License
LETTER
Reproducibility issues in science, is P value really
the only answer?
Johnson describes the lack of reproducibility
of scientific studies, attributed, according to
the author, to the low level of significance (1).
We appreciate the quality of this work and its
importance for the interpretation of statistical
evidence. These results should be consid-
ered in statistical guidelines. Nevertheless,
we would like to point out some impor-
tant points not thoroughly discussed in this
publication.
Not publishing “nonsignificant” results
leads to the well-known publication bias
whereby studies with low statistical power
are underrepresented. This bias would be-
come more severe, despite recommenda-
tions to allow for publication of “negative”
results. Lowering the significance level will
further increase the type II error, which is
clinically as important as type I error. Fo-
cusing only on the type I error may lead to
an excessive false nondiscovery rate. In the
case of severe diseases, it is not uncom-
mon to fix a significance level at 0.1 (2),
at the early stages, to avoid excluding an
effective treatment. Johnson argues that
this may be corrected by increasing the
sample size. However, increasing the size
of clinical trials will reduce their feasi-
bility and increase their duration. Aside
from these issues, including more patients
means exposing more patients to an ex-
perimental treatment and may challenge
the equipoise concept.
The issue of fixing a threshold defining sig-
nificance refers to the Fisher–Pearson con-
troversy. Estimating a P value is needed to
quantify the strength of evidence. However,
fixing a threshold is needed to make a de-
cision controlling for the risk of type I
and type II error. Actually, regarding
the issue addressed by Johnson, it would
be interesting to assess if a priori specifi-
cation of the threshold is required, or if
research results could be compared using
the P value and the magnitude of the
tested statistic.
The issue of significance level is only the
tip of the iceberg. Indeed, design issues
should not be overlooked when discussing
lack of reproducibility. Selection bias leads
to extrapolation of results to a population
different from the target population (3).
Furthermore, the “poor reporting” practice
highlighted by Altman et al. (4) and the
lack of compliance to reporting recommen-
dations (e.g., Consolidated Standards of
Reporting Trials) hinder a proper assess-
ment of the quality of the study and hide
selection bias or misuse of statistical tests;
the latter leads to nonreproducibility of the
reported research. In an extreme example,
monthly American Air passengers and the
Australian electricity production in the
late 1950s are highly correlated (Pearson’s
correlation = 0.88, P = 8.8 × 10−13) with-
out any meaning.
The causality criteria defined by Hill (5)
highlight other important considerations
in the interpretation of results. Reliance on
P values remains surprisingly widespread, but
good decision making depends on the mag-
nitude of effects, the plausibility of scientific
explanations of the mechanism, and the re-
producibility of the findings by others.
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